347195-55-5

Usage

Uses

Used in Organic Synthesis:
(R)-3-N-Benzyl-2-ethyl piperazine is used as a building block in organic synthesis for the creation of various pharmaceuticals and bioactive molecules. Its unique structure allows for the development of new compounds with specific therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (R)-3-N-Benzyl-2-ethyl piperazine is utilized as a key component in the synthesis of drugs, contributing to the discovery and design of novel therapeutic agents.
Used in Pharmaceutical Development:
(R)-3-N-Benzyl-2-ethyl piperazine is employed as a precursor in pharmaceutical development, aiding in the formulation of new drugs with potential applications in treating a range of diseases and conditions.
Used in Research and Development of Therapeutic Agents:
(R)-3-N-BENZYL-2-ETHYL PIPERAZINE is also used in research and development for its potential pharmacological activities, exploring its role as a therapeutic agent in the treatment of various diseases and conditions, thereby expanding the scope of available medical treatments.

InChI:InChI=1/C13H20N2/c1-2-13-11-15(9-8-14-13)10-12-6-4-3-5-7-12/h3-7,13-14H,2,8-11H2,1H3/t13-/m1/s1

Upstream product

• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 674791-89-0 (S)-1-benzyl-3-ethylpiperazine-2-one 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 142301-65-3 N-Allyl-N-benzyltrifluoroacetamide 
• 142301-66-4 N-benzyl-2,2,2-trifluoro-N-(2-oxoethyl)acetamide 
• 7387-69-1 N-benzyl-2,2,2-trifluoroacetamide 
• 674283-98-8 piperazinone 
• 100-39-0 benzyl bromide 
• 13961-37-0 2-ethylpiperazine 
• 100-52-7 benzaldehyde 
• 325145-36-6 (3S)-3-ethyl-1-(phenylmethyl)-2,5-piperazinedione 

Downstream Products

• 438049-13-9 (R)-2-Ethyl-piperazine-1-carboxylic acid 3-(2-cyclohexyl-ethoxy)-2,6-difluoro-benzyl ester hydrochloride 
• 438049-18-4 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-(3-phenoxy-propoxy)-benzyl ester hydrochloride 
• 438049-05-9 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-(3-phenyl-propoxy)-benzyl ester hydrochloride 
• 438048-92-1 (R)-2-Ethyl-piperazine-1-carboxylic acid 5-(2-cyclohexyl-ethoxy)-2-fluoro-benzyl ester hydrochloride 
• 438049-06-0 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-(4-methyl-benzyloxy)-benzyl ester hydrochloride 
• 438049-07-1 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-(3-methyl-benzyloxy)-benzyl ester hydrochloride 
• 438049-08-2 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-(2-methyl-benzyloxy)-benzyl ester hydrochloride 
• 438049-12-8 (R)-2-Ethyl-piperazine-1-carboxylic acid 3-cyclobutylmethoxy-2,6-difluoro-benzyl ester hydrochloride 
• 438049-02-6 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-3-pentyloxy-benzyl ester hydrochloride 
• 438048-91-0 (R)-2-Ethyl-piperazine-1-carboxylic acid 5-cyclohexylmethoxy-2-fluoro-benzyl ester hydrochloride 
• 438048-97-6 (R)-2-Ethyl-piperazine-1-carboxylic acid 2-fluoro-5-(3-phenoxy-propoxy)-benzyl ester hydrochloride 
• 438049-04-8 (R)-2-Ethyl-piperazine-1-carboxylic acid 3-benzyloxy-2,6-difluoro-benzyl ester hydrochloride 
• 438049-09-3 (R)-2-Ethyl-piperazine-1-carboxylic acid 3-(3,3-dimethyl-butoxy)-2,6-difluoro-benzyl ester hydrochloride 
• 438049-17-3 (R)-2-Ethyl-piperazine-1-carboxylic acid 3-(2-ethoxy-ethoxy)-2,6-difluoro-benzyl ester hydrochloride 

Relevant academic research and scientific papers

Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors

We herein describe the results of further evolution of glycogen synthase kinase (GSK)-3β inhibitors from our promising compounds containing a 3-methylmorpholine moiety. Transformation of the morpholine moiety into a piperazine moiety resulted in potent GS

Catalytic Asymmetric Synthesis of Morpholines. Using Mechanistic Insights to Realize the Enantioselective Synthesis of Piperazines

An efficient and practical catalytic approach for the enantioselective synthesis of 3-substituted morpholines through a tandem sequential one-pot reaction employing both hydroamination and asymmetric transfer hydrogenation reactions is described. Starting from ether-containing aminoalkyne substrates, a commercially available bis(amidate)bis(amido)Ti catalyst is utilized to yield a cyclic imine that is subsequently reduced using the Noyori-Ikariya catalyst, RuCl [(S,S)-Ts-DPEN] (η6-p-cymene), to afford chiral 3-substituted morpholines in good yield and enantiomeric excesses of >95%. A wide range of functional groups is tolerated. Substrate scope investigations suggest that hydrogen-bonding interactions between the oxygen in the backbone of the ether-containing substrate and the [(S,S)-Ts-DPEN] ligand of the Ru catalyst are crucial for obtaining high ee's. This insight led to a mechanistic proposal that predicts the observed absolute stereochemistry. Most importantly, this mechanistic insight allowed for the extension of this strategy to include N as an alternative hydrogen bond acceptor that could be incorporated into the substrate. Thus, the catalytic, enantioselective synthesis of 3-substituted piperazines is also demonstrated.

Novel Compounds

The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS

Compounds of formulae I, II and III: are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES

The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Formula (I)

PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS

Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders r

Benzofurylpiperazine serotonin agonists

The present invention provides serotonergic benzofurans of Formula I: where R is methyl or ethyl, or pharmaceutically acceptable acid addition salts thereof.

Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2creceptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.